CONTEXT: In the last few years, the treatment of renal cell carcinoma (RCC) has progressed significantly, and some histopathologic issues have become important for selection and follow-up after medical and surgical therapies. OBJECTIVE: The aim of this collaborative article is to review the most recent literature on the role of traditional histopathologic features obtained from renal core biopsy or nephrectomy specimens in the management of confined, locally advanced, and metastatic RCC. EVIDENCE ACQUISITION: A nonsystematic review of the literature was performed in April 2010 using the Medline database. Multiple free-text searches were performed for the following items: renal cell carcinoma, clear cell, papillary, chromophobe, histologic* subtype*, histotype*, nuclear grade*, necrosis, sarcomatoid differentiation, biopsy, molecular marker*, and cytogenetic marker*. A total of 2369 records were retrieved from Medline, and 263 full-text studies were considered and partially included in the present review. A panel of experts reached consensus on the main subheadings of this paper. EVIDENCE SYNTHESIS: Core needle biopsies can provide important information that is useful to avoid the overtreatment of benign tumors and to help plan watchful waiting or minimally invasive treatments in selected patients. Tumor histotype is fundamental in the pathologic report. In the context of integrated prognostic systems, the combination of the most important clinical and pathologic factors (TNM stage, Fuhrman nuclear grade, presence of necrosis, microvascular invasion, and sarcomatoid dedifferentiation) allows us to reach a high prognostic accuracy. These models can be used to select patients suitable for adjuvant protocols, to design an appropriate follow-up schedule, and to provide careful patient counseling. Molecular and cytogenetic markers should be further evaluated. CONCLUSIONS: The histopathologic definition of parenchymal epithelial renal tumors is fundamental to plan the management and follow-up of patients with locally confined, locally advanced, and metastatic RCC.
CONTEXT: In the last few years, the treatment of renal cell carcinoma (RCC) has progressed significantly, and some histopathologic issues have become important for selection and follow-up after medical and surgical therapies. OBJECTIVE: The aim of this collaborative article is to review the most recent literature on the role of traditional histopathologic features obtained from renal core biopsy or nephrectomy specimens in the management of confined, locally advanced, and metastatic RCC. EVIDENCE ACQUISITION: A nonsystematic review of the literature was performed in April 2010 using the Medline database. Multiple free-text searches were performed for the following items: renal cell carcinoma, clear cell, papillary, chromophobe, histologic* subtype*, histotype*, nuclear grade*, necrosis, sarcomatoid differentiation, biopsy, molecular marker*, and cytogenetic marker*. A total of 2369 records were retrieved from Medline, and 263 full-text studies were considered and partially included in the present review. A panel of experts reached consensus on the main subheadings of this paper. EVIDENCE SYNTHESIS: Core needle biopsies can provide important information that is useful to avoid the overtreatment of benign tumors and to help plan watchful waiting or minimally invasive treatments in selected patients. Tumor histotype is fundamental in the pathologic report. In the context of integrated prognostic systems, the combination of the most important clinical and pathologic factors (TNM stage, Fuhrman nuclear grade, presence of necrosis, microvascular invasion, and sarcomatoid dedifferentiation) allows us to reach a high prognostic accuracy. These models can be used to select patients suitable for adjuvant protocols, to design an appropriate follow-up schedule, and to provide careful patient counseling. Molecular and cytogenetic markers should be further evaluated. CONCLUSIONS: The histopathologic definition of parenchymal epithelial renal tumors is fundamental to plan the management and follow-up of patients with locally confined, locally advanced, and metastatic RCC.
Authors: Stephan Kruck; Aristoteles G Anastasiadis; Ute Walcher; Arnulf Stenzl; Thomas R W Herrmann; Udo Nagele Journal: World J Urol Date: 2012-01-24 Impact factor: 4.226
Authors: Mehrad Adibi; Arun Z Thomas; Leonardo D Borregales; Megan M Merrill; Rebecca S Slack; Hsiang-Chun Chen; Kanishka Sircar; Paari Murugan; Pheroze Tamboli; Eric Jonasch; Nizar M Tannir; Surena F Matin; Christopher G Wood; Jose A Karam Journal: Urol Oncol Date: 2015-05-23 Impact factor: 3.498
Authors: Grant D Stewart; Fiach C O'Mahony; Thomas Powles; Antony C P Riddick; David J Harrison; Dana Faratian Journal: Nat Rev Urol Date: 2011-04-12 Impact factor: 14.432
Authors: Jeffrey C Gahan; Miguel Gosalbez; Travis Yates; Ezekiel E Young; Diogo O Escudero; Andrew Chi; Michael Garcia-Roig; Ramgopal Satyanarayana; Mark S Soloway; Vincent G Bird; Vinata B Lokeshwar Journal: J Urol Date: 2012-01-15 Impact factor: 7.450
Authors: Sabine Brookman-May; Matthias May; Vincenzo Ficarra; Manuela Christine Kainz; Karin Kampel-Kettner; Stephanie Kohlschreiber; Valentina Wenzl; Meike Schneider; Maximilian Burger; Wolf F Wieland; Wolfgang Otto; Derya Tilki; Christian Gilfrich; Markus Hohenfellner; Sascha Pahernik; Thomas F Chromecki; Christian Stief; Richard Zigeuner Journal: World J Urol Date: 2012-08-19 Impact factor: 4.226
Authors: M Pichler; G C Hutterer; C Stoeckigt; T F Chromecki; T Stojakovic; S Golbeck; K Eberhard; A Gerger; S Mannweiler; K Pummer; R Zigeuner Journal: Br J Cancer Date: 2013-02-05 Impact factor: 7.640